Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OBT-700 + PDL1
- Development stage
- Preclinical
- Lead developer
- Oxford BioTherapeutics
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
OBT-700 + PDL1 is an **Oxford BioTherapeutics** oncology pipeline asset listed on the company's pipeline as an **IO bispecific** for **solid tumours** with an **undisclosed target** beyond the PD-L1 component. Publicly available information is limited: the program appears to be a **bispecific immuno-oncology antibody combination construct** involving **OBT-700** and a **PD-L1-binding arm**, but the exact molecular composition, partner target, antibody format, and clinical development details have not been publicly disclosed. Based on the sponsor pipeline entry, it is best characterized as a **preclinical bispecific immunotherapy program for solid tumors** rather than a fully described named drug.
- Other names
- OBT-700/PDL1
02
Targets
CD274 (Programmed cell death protein 1 ligand 1)
Beyond the preview
Go deeper on OBT-700 + PDL1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OBT-700 + PDL1.